Are your value-added services (VAS) in oncology meeting the needs of payers as well as patients and physicians? Payers are increasingly taking interest in beyond-the-pill services that improve patient adherence, positively impact health outcomes and reduce the overall cost burden. Yet pharma does not consult with payers on VAS development and fails to fully utilize the real world data VAS generates to build evidence of a product’s value. The value of VAS is being recognized by payers and, ultimately, could influence reimbursement and formulary decisions.
This expert report provides a full understanding of what payers would like to see in VAS oncology programs, the current services they value and what factors pharma should take into account when creating VAS offerings.